How Many Doses Vial LL-37? (Reconstitution & Storage Guide)

How Many Doses Vial LL-37? (Reconstitution & Storage Guide)

Research-grade peptides cost too much to waste through improper reconstitution or inaccurate dosing calculations. One of the most common questions researchers ask when working with LL-37. A naturally occurring antimicrobial peptide with applications in immune research, wound healing studies, and inflammation protocols. Is exactly how many usable doses a single vial provides. The answer isn't printed on the label because it depends entirely on your reconstitution method and target dose per administration.

We've worked with hundreds of research teams ordering LL-37 through Real Peptides. The calculation errors happen at reconstitution, not during protocol execution. And they're entirely preventable once you understand the relationship between lyophilised powder mass, bacteriostatic water volume, and target dose concentration.

How many doses does a vial of LL-37 provide?

A standard 5mg LL-37 vial reconstituted with 2ml bacteriostatic water yields 20 doses at 250mcg per dose, or 10 doses at 500mcg per dose. The total number of doses per vial depends on three variables: the peptide mass in milligrams (typically 2mg, 5mg, or 10mg per vial), the volume of bacteriostatic water used for reconstitution, and your target dose per injection. Calculate doses using this formula: (peptide mass in mcg ÷ reconstitution volume in ml) × injection volume in ml = dose per administration.

Most researchers don't account for the fact that peptide concentration. Not vial size. Determines how many doses you can extract. A 5mg vial isn't inherently '5 doses' or '10 doses'. It's a pool of peptide that you subdivide based on your protocol requirements and the dilution ratio you choose during reconstitution.

Understanding LL-37 Vial Concentrations and Reconstitution Math

LL-37 (also known as cathelicidin antimicrobial peptide) is supplied as lyophilised powder in sealed glass vials, typically in 2mg, 5mg, or 10mg quantities. The peptide arrives as a freeze-dried cake at the bottom of the vial. This form is stable at -20°C for extended periods but cannot be used until reconstituted with bacteriostatic water. The number of doses vial LL-37 provides is determined at the moment you add that water, because reconstitution volume controls final concentration.

Here's the calculation framework: if you reconstitute a 5mg (5000mcg) vial with 2ml bacteriostatic water, your final concentration is 2500mcg/ml. If your protocol calls for 250mcg per dose, you'll draw 0.1ml (100 units on a standard insulin syringe) per injection. Yielding 20 total doses from that vial. If your target dose is 500mcg, you'll draw 0.2ml per injection, yielding 10 doses. The peptide mass doesn't change, but your chosen dilution and dose size determine how many administrations you can perform.

Bacteriostatic water. Sterile water containing 0.9% benzyl alcohol as a preservative. Is the standard reconstitution solvent for research peptides. Once mixed, LL-37 remains stable at 2–8°C (standard refrigeration) for approximately 28 days. Any temperature excursion above 8°C accelerates peptide degradation, and freezing reconstituted peptide causes structural damage that standard laboratory assessment cannot detect. Most dosing errors stem from incorrect syringe volume measurement or using an inappropriate reconstitution volume that makes precise small-dose extraction difficult.

Researchers working with immune modulation studies often use doses between 200–500mcg per administration, while wound healing protocols may explore higher concentrations. The mechanism of action. LL-37 binds lipopolysaccharide (LPS) on bacterial cell walls and modulates immune cell chemotaxis. Remains consistent across dose ranges, but the therapeutic window for specific endpoints varies by study design. Real Peptides synthesizes LL-37 through solid-phase peptide synthesis with amino-acid sequencing verified via HPLC, ensuring that labeled mass reflects actual peptide content within ±5% tolerance.

How to Calculate Doses Per Vial Based on Your Protocol

Dose calculation requires three inputs: peptide mass (in micrograms), total reconstitution volume (in milliliters), and target dose per injection (in micrograms). Convert all units before calculating. A 5mg vial equals 5000mcg. If you reconstitute with 2.5ml bacteriostatic water, your concentration is 5000mcg ÷ 2.5ml = 2000mcg/ml. If your protocol specifies 400mcg per dose, divide total peptide mass by dose size: 5000mcg ÷ 400mcg = 12.5 doses (realistically 12 full doses, accounting for dead space in the vial and syringe).

Many researchers find it easier to choose reconstitution volume that produces a round-number concentration. For a 5mg vial, reconstituting with 2ml yields 2500mcg/ml. Making it simple to draw 0.1ml (250mcg), 0.2ml (500mcg), or 0.16ml (400mcg) per dose. Reconstituting the same vial with 5ml yields 1000mcg/ml, which simplifies drawing larger volumes but requires more bacteriostatic water and increases total injection volume per administration. Subcutaneous injection volumes above 0.5ml per site can cause discomfort in animal models, so balancing concentration with injection volume matters for protocol adherence.

Insulin syringes marked in units (U-100 scale) are the standard tool for peptide administration. On a U-100 syringe, 0.1ml equals 10 units, 0.2ml equals 20 units, and 0.5ml equals 50 units. Researchers unfamiliar with this scale sometimes confuse 'units' with micrograms of peptide, leading to ten-fold dosing errors. The syringe measures volume (ml), not mass (mcg). Concentration determines how much peptide is contained in that volume. A detailed reconstitution log with concentration, target dose, and corresponding syringe volume eliminates this error.

When calculating how many doses vial LL-37 provides for multi-week protocols, account for wastage. Approximately 0.1–0.2ml of reconstituted solution remains in the vial as dead space that cannot be drawn even with careful technique. For a 2ml reconstitution, this represents roughly 5–10% loss. Plan accordingly if your study requires exact dose counts across a fixed timeline. Ordering an additional vial ensures protocol continuity if wastage or contamination occurs.

Storage, Stability, and Dose Integrity Across the Study Timeline

LL-37 peptide stability is temperature-dependent and time-sensitive once reconstituted. Lyophilised LL-37 stored at -20°C in sealed vials maintains structural integrity for 12–24 months from the date of manufacture. Once you add bacteriostatic water, stability drops to approximately 28 days under continuous refrigeration at 2–8°C. This imposes a practical ceiling on how many doses vial LL-37 can realistically deliver in protocols lasting longer than four weeks. If your study timeline exceeds 28 days, you'll need multiple vials even if the total peptide mass theoretically covers your full dose requirement.

Temperature excursions are the primary cause of peptide degradation after reconstitution. A single exposure above 8°C for more than four hours can denature the peptide structure. The solution may appear visually unchanged, but potency is compromised. Refrigerated storage between doses is non-negotiable. Researchers conducting field studies or multi-site protocols use insulin cooler packs designed to maintain 2–8°C for 36–48 hours, but these are stopgap solutions, not long-term storage. Freezing reconstituted LL-37 causes ice crystal formation that disrupts the peptide backbone. Thawed peptide is structurally damaged even if it re-solubilizes.

Light exposure accelerates peptide oxidation. Store reconstituted vials in amber glass or wrap clear vials in aluminum foil to block UV and visible light. Bacteriostatic water's benzyl alcohol preservative inhibits bacterial growth but does not prevent oxidative degradation of the peptide itself. Some research teams aliquot reconstituted peptide into multiple sterile vials immediately after mixing, storing only the current-use vial in the refrigerator and keeping backup aliquots frozen until needed. But this introduces freeze-thaw risk and is generally discouraged unless protocol demands dictate it.

Contamination risk increases with repeated needle punctures through the vial's rubber stopper. Each draw introduces potential particulate matter or microbial contamination, even with alcohol swab sterilization. Best practice: use a fresh needle for every draw, swab the stopper with 70% isopropyl alcohol before each puncture, and discard any vial showing visible particulate matter or cloudiness regardless of remaining volume. At Real Peptides, every LL-37 vial is synthesized under strict sterile conditions, but post-reconstitution contamination is entirely user-dependent.

LL-37 Vial Sizes: Dose Yield Comparison

The table below compares dose yields across common LL-37 vial sizes, reconstitution volumes, and target doses. This is the practical reference for calculating how many doses vial LL-37 provides based on your specific protocol requirements.

Reconstitution volume choice affects both concentration and ease of measurement. Higher reconstitution volumes (4–5ml) produce lower concentrations, requiring larger syringe draws per dose. This reduces measurement error for small doses but increases injection volume. Lower reconstitution volumes (1–2ml) produce higher concentrations, allowing smaller injection volumes but requiring more precise syringe technique. The 2ml reconstitution for a 5mg vial is the de facto standard because it yields 2500mcg/ml. A concentration that accommodates both 250mcg and 500mcg doses with straightforward syringe volume calculation.

Key Takeaways

• A 5mg LL-37 vial reconstituted with 2ml bacteriostatic water yields 20 doses at 250mcg each, or 10 doses at 500mcg each. Dose count depends on your chosen protocol, not the vial size alone.
• Calculate your concentration before drawing doses: (peptide mass in mcg ÷ reconstitution volume in ml) = concentration in mcg/ml, then (target dose in mcg ÷ concentration) = injection volume in ml.
• Reconstituted LL-37 remains stable for 28 days when refrigerated continuously at 2–8°C. Any temperature excursion above 8°C or freezing after reconstitution compromises peptide integrity.
• Dead space in vials and syringes accounts for 5–10% wastage. Plan for 10–15% more peptide than your theoretical dose calculation suggests if protocol precision is critical.
• Insulin syringes measure volume in ml (or 'units' where 10 units = 0.1ml), not peptide mass in mcg. Confusion between these units is the most common dosing error researchers make.

What If: LL-37 Dosing and Storage Scenarios

What If I Reconstitute LL-37 But Don't Use It for Two Weeks?

Refrigerate the vial continuously at 2–8°C and it remains viable for the full 28-day stability window from the day of reconstitution. Mark the reconstitution date on the vial label with permanent marker. Do not freeze it, and do not leave it at room temperature for more than 30 minutes during a single use. If the vial has been refrigerated without interruption and shows no cloudiness or particulate matter, it's usable through day 28.

What If My Protocol Requires 35 Doses But a Single 5mg Vial Only Provides 20?

Order two vials. Reconstitute the first vial at the start of your protocol and refrigerate it. Reconstitute the second vial on day 15 or when the first vial is depleted, whichever comes first. Staggering reconstitution ensures that neither vial exceeds the 28-day stability limit. Attempting to double-concentrate a single vial by using half the standard bacteriostatic water volume makes dose measurement more error-prone without extending usable timeline.

What If I Accidentally Left My Reconstituted LL-37 Vial at Room Temperature Overnight?

Discard it. Peptides degrade rapidly above 8°C. An overnight ambient temperature exposure (typically 20–25°C) for 8–12 hours likely caused irreversible structural damage. Reconstituted peptide cannot be visually assessed for potency loss; degraded LL-37 looks identical to fresh peptide. Using compromised peptide introduces uncontrolled variables that invalidate study results. The financial loss is real, but the research integrity loss from using degraded peptide is worse.

What If I'm Not Sure How Much Volume I Drew Into the Syringe?

Discard that dose and draw a fresh one. Subcutaneous administration of an unknown dose introduces confounding variables your protocol cannot account for. Insulin syringes have clear unit markings. If you cannot confidently read the plunger position against the scale, the syringe may be defective or you may need better lighting. Use a magnifying glass if necessary, and always double-check the volume before administration. Dose consistency is non-negotiable in controlled research.

The Unvarnished Truth About LL-37 Dose Calculation

Here's the honest answer: most researchers waste at least one vial before they internalize the reconstitution math. The confusion isn't about the peptide. It's about unit conversion, syringe scales, and the gap between theoretical dose counts and real-world wastage. A 5mg vial doesn't 'contain 20 doses' in any inherent way. It contains 5000 micrograms of peptide that you choose to subdivide into 20 portions, or 10 portions, or 25 portions based on your dilution choice and target dose. The vial is a raw material pool, not a pre-portioned product.

The second hard truth: most contamination and degradation events happen after reconstitution, not before. Real Peptides guarantees peptide purity and sequence accuracy at the point of shipping. We synthesize every batch through solid-phase peptide synthesis with HPLC verification and ship lyophilised vials that remain stable for months under proper storage. Once you add bacteriostatic water, responsibility for stability shifts entirely to storage conditions, sterile technique, and timeline adherence. A vial stored at 10°C instead of 4°C may look fine but deliver inconsistent results across doses. Temperature logging isn't paranoia. It's quality control.

If you're running a pilot study and unsure how many doses vial LL-37 will realistically provide given your reconstitution method and target dose, order one extra vial as a buffer. The cost of an unused vial is trivial compared to the cost of a mid-protocol peptide shortage that forces you to pause data collection or restart the study. Calculate conservatively, reconstitute precisely, and track every dose you draw. That discipline is what separates publishable research from wasted effort.

Researchers interested in immune modulation peptides beyond LL-37 often explore complementary compounds. Thymosin Alpha 1 for T-cell function studies or BPC-157 for tissue repair protocols. Real Peptides maintains the same synthesis standards and purity verification across our full catalog, ensuring that every peptide ships with the exact amino-acid sequencing and concentration your protocol requires.

Dose calculation isn't the hard part. It's high school algebra. The hard part is maintaining sterile technique, consistent refrigeration, and accurate record-keeping across a multi-week timeline when laboratory priorities shift and shortcuts become tempting. That discipline determines whether your many doses vial LL-37 provides turn into usable data or compromised results.